FDA Dense Breast Notification Requirements: What Mammography Facilities Need to Know

In March 2023, the FDA finalized an updated rule under MQSA that requires all mammography facilities in the United States to notify patients about their breast density. The rule took effect on September 10, 2024, and every facility performing mammography must now comply.

This guide explains the FDA dense breast notification requirements, what your facility must do, and how breast density affects both clinical decision-making and equipment strategy.

What the FDA Dense Breast Rule Requires

The updated MQSA regulation establishes a national standard for breast density reporting in mammography. Prior to this rule, density notification requirements varied by state, with some states mandating detailed disclosure and others having no requirements at all. The federal rule creates a uniform baseline that applies to every facility nationwide.

Key Requirements

• Every mammography report sent to patients must include information about breast density. This is a mandatory component of the lay summary that MQSA already requires facilities to provide.
• The notification must use one of two categories of standardized language defined by the FDA: one for patients with dense breast tissue (categories C and D) and one for patients without dense breast tissue (categories A and B).
• The dense tissue notification must inform the patient that dense breast tissue can make it harder to find cancer on a mammogram and that dense tissue may also increase the risk of developing breast cancer.
• The notification must recommend that patients with dense breasts talk with their healthcare provider about breast density, the risks associated with dense tissue, and whether additional screening tests might be appropriate.
• Reports to referring healthcare providers must include an assessment of breast density using the established BI-RADS classification system.

The Four Breast Density Categories

Breast density is classified using the ACR BI-RADS (Breast Imaging Reporting and Data System) lexicon into four categories based on the proportion of fibroglandular tissue visible on the mammogram.

Category	Description	Approximate Prevalence	FDA Notification Category
A	Almost entirely fatty	~10% of women	Not dense
B	Scattered areas of fibroglandular density	~40% of women	Not dense
C	Heterogeneously dense	~40% of women	Dense
D	Extremely dense	~10% of women	Dense

Approximately 50% of women undergoing mammography have dense breast tissue (categories C or D). This means roughly half of all mammography patients will receive the dense tissue notification.

Why Breast Density Matters Clinically

Breast density affects mammography in two clinically significant ways.

The Masking Effect

Dense fibroglandular tissue appears white on a mammogram. Cancers also appear white. When cancer develops within dense tissue, it can be obscured or "masked" by the surrounding dense tissue, making detection significantly more difficult. Studies show that mammography sensitivity (the ability to detect cancer when it is present) drops from approximately 85-90% in fatty breasts to 60-70% in extremely dense breasts.

Independent Risk Factor

Dense breast tissue is an independent risk factor for breast cancer. Women with extremely dense breasts (category D) have a 4 to 6 times higher risk of developing breast cancer compared to women with almost entirely fatty breasts (category A). Women with heterogeneously dense breasts (category C) have approximately 1.2 to 2 times the average risk.

The combination of reduced detection sensitivity and increased cancer risk makes breast density one of the most important factors in mammography screening strategy.

What Facilities Must Do to Comply

Facilities should take the following steps to ensure full compliance with the federal dense breast notification requirements.

• Update patient lay summary templates: Modify the written results letters sent to patients to include the FDA-mandated breast density language. Use the exact standardized language specified in the regulation or language that is substantially similar in meaning.
• Ensure interpreting physicians assign density categories: Every mammography interpretation must include a BI-RADS breast density assessment (A through D). This assessment drives which notification language the patient receives.
• Update report templates in your reporting system: Configure your mammography reporting workstation and RIS to include density categorization as a required field and auto-populate the appropriate patient notification language.
• Review state-specific requirements: Some states have density notification laws that are more stringent than the federal rule. Facilities in those states must comply with whichever standard is more protective of patients. Check your state's requirements to ensure your notification language and process meet both federal and state standards.
• Train staff: Ensure interpreting physicians, technologists, and administrative staff understand the new requirements, the density categories, and how to handle patient questions about breast density.
• Prepare for patient inquiries: Expect an increase in patient questions and requests for supplemental screening. Develop talking points for front-desk staff and technologists. Have referral pathways ready for patients who want additional evaluation.

State vs Federal Density Notification Laws

Before the federal rule, 38 states and the District of Columbia had already enacted their own breast density notification laws. These laws vary significantly in specificity and scope. The federal rule establishes a national minimum standard but does not preempt state laws that provide greater protection to patients.

Facilities must comply with the more stringent requirement, whether federal or state. For example, if your state law requires specific language about supplemental screening options such as breast ultrasound or MRI, your notification must include that language even though the federal rule does not specifically mandate it.

Impact on Equipment and Technology

The federal density notification rule is accelerating several technology trends in mammography that directly affect equipment purchasing and service decisions.

Increased Demand for 3D Tomosynthesis

Digital breast tomosynthesis (DBT) creates a pseudo-3D image by acquiring multiple low-dose projections as the X-ray tube moves through an arc. This technology reduces the tissue overlap that causes the masking effect in dense breasts, improving cancer detection rates by 20-40% compared to 2D mammography alone. As more patients learn about their breast density and seek better screening, facilities without 3D capability face competitive and clinical pressure to upgrade.

AI-Assisted Detection

Artificial intelligence software designed for mammography, such as Hologic's Genius AI Detection, is specifically engineered to improve cancer detection in dense breast tissue by identifying subtle patterns that human readers may miss. Facilities looking to maximize detection performance in their dense breast population are increasingly adopting these tools.

Contrast-Enhanced Mammography

Contrast-enhanced spectral mammography (CESM) uses iodinated contrast agent to highlight areas of increased vascularity, making cancers visible even in the densest breast tissue. While still relatively uncommon, CESM is growing as an alternative to breast MRI for women with dense breasts. Systems that support CESM, such as GE Healthcare's SenoBright HD, offer facilities an additional clinical tool for the dense breast population.

How ARRAD Helps Facilities Prepare

The dense breast notification rule is driving demand for more capable mammography technology. ARRAD helps facilities respond to this shift with equipment solutions that directly address the dense breast challenge.

• Hologic 3D systems with Genius AI: ARRAD supplies both new and refurbished Hologic Dimensions and 3DQuant systems that support Genius AI Detection, providing the advanced tomosynthesis and AI-assisted reading capability that performs best in dense breast tissue.
• System upgrades: Facilities with existing 2D-only mammography systems can upgrade to 3D-capable platforms. ARRAD evaluates your current system and provides options for upgrade or replacement.
• Multi-brand options: ARRAD supports Hologic, GE Healthcare, and Fujifilm mammography platforms, allowing facilities to choose the technology that best fits their clinical workflow and budget.
• Service and maintenance: Advanced mammography technology requires expert service to maintain peak performance. ARRAD's factory-trained engineers provide PM and repair service nationwide to keep your systems running at the performance levels your dense breast patients depend on.

Prepare Your Facility for Density Reporting

The FDA dense breast notification requirement is now in effect. Facilities that have not yet updated their reporting processes, patient communications, and clinical workflows should act immediately to ensure compliance.

If the density notification rule is prompting your facility to consider upgrading or adding mammography technology, ARRAD can help you evaluate your options and implement the right solution.

Contact ARRAD today at 877.299.8303 or visit our contact page to discuss mammography equipment options. For OEM replacement parts, visit radmedparts.com.